Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:46 AM
Ignite Modification Date:
2025-12-25 @ 3:46 AM
NCT ID:
NCT01677702
Eligibility Criteria:
Inclusion Criteria:
* Age 6 to 12 years, catch cold for 4 to 6 times in last year;
* Age 35 to 45 years, catch cold for 4 to 6 times in recent 3 month;
* Age 60 to 75 years, catch cold for 4 to 6 times in last year;
* BMI 18.5to 29.9kg/m2;
* Able to understand the nature and purpose of the study including potential risks and side effects
Exclusion Criteria:
* Recent (within 6 months of screening) been vaccinated influenza vaccine, or recent (within 15 days of screening) been vaccinated ther vaccines;
* Suffering from rhinitis chronic, laryngitis, labored breathing that similar to flu symptoms. Such as chronic allergic rhinitis, asthma, COPD;
* Long-term use of any prescription or OTC medication that inhibit or prevent flu symptoms, including but not limited to, antihistamine, pectoral, high doses of vitamin C;
* Recent use (within 3 months of screening) of any prescription or OTC medication that significantly affects immune response, such as antibiotic;
* Known allergies to dairy and any substance in the study product;
* History of alcohol, drug, or medication abuse
* Pregnant or breastfeeding women
* Recent daily use (within 3 months of screening) of any probiotics, clabber or yogurt;
* Any comorbidity that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
6 Years
Maximum Age:
75 Years
Study:
NCT01677702
Study Brief:
Protocol Section:
NCT01677702